Literature DB >> 11357884

Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.

J Szebeni1, C R Alving, S Savay, Y Barenholz, A Priev, D Danino, Y Talmon.   

Abstract

We reported earlier that the anticancer drug paclitaxel (Taxol) activated the complement (C) system in human serum in vitro, raising the possibility that C activation might play a role in the ill-understood hypersensitivity reactions (HSRs) to this drug [J. Natl. Cancer Inst. 90 (1998) 300]. In pursuing the mechanism of C activation by Taxol, the present study provided evidence that dilution of the injection concentrate in aqueous solvents led to the formation of micelles and needle-like structures, both of which caused C activation in vitro. Micelles were formed mainly from Cremophor EL (CrEL), the nonionic emulsifier vehicle of paclitaxel, whose level in Taxol infusion exceeded its critical micelle concentration by at least 400-fold. CrEL micelles were shown by quasi-elastic light scattering and cryo-transmission electron microscopy (cryo-TEM) to be spherical with diameters in the 8-22 nm range; however, de novo formation of 50-300 nm microdroplets following incubation with human plasma suggested further fundamental structural transformation in blood. The needle-like structures extended to the multimicron range and were shown by electron diffraction to be crystalline paclitaxel. Taxol-induced C activation was manifested in varying rises of serum C3a-desarg, iC3b and SC5b-9. The causal role of CrEL micelles in C activation was demonstrated by the fact that filtration of aqueous solutions of Taxol or pure CrEL via 30-kDa cutoff filters eliminated, while the filter retentate restored C activation. C activation by Taxol was also inhibited by 10 mg/ml human immunoglobulin (IVIG). If proven clinically, HSRs to Taxol may represent a hitherto vaguely classified adverse drug reaction recently called C activation-related pseudoallergy (CARPA) [Circulation 99 (1999) 2302].

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357884     DOI: 10.1016/s1567-5769(01)00006-6

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  26 in total

Review 1.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

2.  Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.

Authors:  Napa Parinyanitikul; Walailuk Tanpipattanakul; Nattaya Poovorawan; Thanapoom Rattananupong; Poranee Laoitthi; Piyada Sithidetphaiboon; Suebpong Thanasanvimon; Virote Sriuranpong
Journal:  Support Care Cancer       Date:  2018-02-12       Impact factor: 3.603

Review 3.  Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.

Authors:  Liza C Villaruz; Mark A Socinski
Journal:  Eur J Cancer       Date:  2016-02-12       Impact factor: 9.162

4.  Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.

Authors:  José Hureaux; Frédéric Lagarce; Frédéric Gagnadoux; Marie-Christine Rousselet; Valérie Moal; Thierry Urban; Jean-Pierre Benoit
Journal:  Pharm Res       Date:  2010-03       Impact factor: 4.200

Review 5.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 6.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 7.  Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Authors:  J Szebeni; S Fishbane; M Hedenus; S Howaldt; F Locatelli; S Patni; D Rampton; G Weiss; J Folkersen
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

Review 8.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

9.  Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.

Authors:  Carly F Chisholm; William Behnke; Yekaterina Pokhilchuk; Ashley A Frazer-Abel; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2019-10-28       Impact factor: 3.534

10.  Nanoemulsion for solubilization, stabilization, and in vitro release of pterostilbene for oral delivery.

Authors:  Yue Zhang; Zhenhua Shang; Chunhui Gao; Man Du; Shixia Xu; Haiwen Song; Tingting Liu
Journal:  AAPS PharmSciTech       Date:  2014-05-15       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.